跳至主導覽 跳至搜尋 跳過主要內容

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study

  • Maximilian J. Hochmair*
  • , Alessandro Morabito
  • , Desiree Hao
  • , Cheng Ta Yang
  • , Ross A. Soo
  • , James C.H. Yang
  • , Rasim Gucalp
  • , Balazs Halmos
  • , Lara Wang
  • , Amanda Golembesky
  • , Angela Märten
  • , Tanja Cufer
  • *此作品的通信作者
  • Otto Wagner Hospital
  • IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
  • University of Calgary
  • Chang Gung Memorial Hospital
  • National University Hospital
  • National Taiwan University
  • Yeshiva University
  • Boehringer Ingelheim Taiwan Limited
  • Boehringer Ingelheim GmbH
  • University of Ljubljana

研究成果: 期刊稿件 › 文章 › 同儕審查

94 引文 斯高帕斯(Scopus)

摘要

Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.

原文英語
頁(從 - 到)2861-2874
頁數14
期刊Future Oncology
卷14
發行號27
DOIs
出版品狀態已出版 - 11 2018
對外發佈是

文獻附註

Publisher Copyright:
© 2015 2018 Maximilian Hochmair.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study」主題。共同形成了獨特的指紋。

引用此